New Insights into Molecular Mechanisms of Severe Asthma
Professor Ian Adcock
Professor of Respiratory Cell & Molecular Biology
NHLI, Imperial College London
Severe asthma presents a high disease burden with limited treatment options except for those with T2 high asthma. Most severe asthmatics are non-T2 however. Understanding the molecular pathways that drive non-T2 asthma is essential if we are to effectively treat these patients. Using data from the U-BIOPRED severe asthma cohort we have identified subphenotypes of asthma with distinct driver mechanisms. Some of these vary over time which reflects an impact of the environment and/or therapy on these pathways. We have started to obtain non-invasive biomarkers using eNOSE technology that may provide real-time assessment of underlying disease mechanisms to enable personalised medicine at the individual patient level.
Ian Adcock graduated from St Thomas’ Hospital Medical School in 1987 with a PhD in Molecular Pharmacology. After MRC-funded spells in Edinburgh and at St Georges’ Hospital in London he moved in 1990 to the National Heart and Lung Institute to work with Professor Peter J Barnes on the molecular mechanisms of glucocorticoid action in the lung. In 2004 he became Professor of Respiratory Cell & Molecular Biology at Imperial College London. Dr Adcock serves on the Editorial Board of several Journals including the AJRCCM and ERJ, is a former Head of Assembly 5 (Airway Diseases) (2014-2017) within the ERS and on the ERS and ATS Programme Committees. Dr Adcock is a PI and WP Leader in the EU/EFPIA IMI UBIOPRED initiative to determine biomarkers of severe asthma using integrated ‘omics and clinical features; Head of the U-BIOPRED Alliance; PI in the MRC-ABPI COPD MAP initiative; PI in the MRC-Asthma UK Centre for Asthma and Allergy and a PI in the CRF at the Royal Brompton and Harefield Hospitals.